KRAS Testing Gets On Label Of EGFr Products; Will Tests Get To Clinic Soon?
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen feels the sales impact from excluding KRAS-positive patients from Vectibix treatment has already occurred, but the firms plans to co-market a test kit shortly.
You may also be interested in...
UnitedHealth Cancer Care Pilot Reduced Overall Costs Despite Higher Drug Spending
The bundled payment pilot program resulted in a 34% decrease in overall cancer treatment costs among participating medical centers despite a 179% increase in drug spending, according to results released July 8.
Can Erbitux Make Inroads In First-line Colon Cancer With Approved Companion Dx In Tow?
Erbitux wins FDA approval for first-line metastatic colorectal cancer negative for KRAS mutations detected with a companion diagnostic specifically approved for the drug. In theory, earlier use could help shore up sales. But the drug faces a tough competitor in the dominant Avastin and new products are on the near horizon.
Clinical Trial Regs: FDA Seeks Advice On How To Make Them Better, Faster, Stronger
FDA is holding a two-day public hearing to get input on how to modernize its regulation of clinical trials; stakeholders cite need for innovative trial design, data sharing, guidance on use of biomarkers.